Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: A retrospective analysis

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 171-176

  Pasqualetti, Giuseppe ^a   Ricci, Sergio ^a   Boni, Giuseppe ^a   Tognini, Sara ^a   Polini, Antonio ^a   Mariani, Giuliano ^a   Ferdeghini, Marco ^b   Monzani, Fabio ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Metastasis; Sunitinib; Thyroid cancer; Tyrosin kinase inhibitor

Indexed keywords

RADIOACTIVE IODINE; SUNITINIB; THYROGLOBULIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TARGETING; EPITHELIUM TUMOR; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LUNG HEMORRHAGE; MALE; MEGALOCYTOSIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84861762816     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604572     Document Type: Article

References (38)

1. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-6.
2. Ambrosetti MC, Colato C, Dardano A, Monzani F, Ferdeghini M. Radioiodine ablation: When and how. Q J Nucl Med Mol Imaging 2009; 53: 473-81.
3. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996; 3: 534-8.
4. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-42.
5. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007; 110: 1451-6.
6. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997; 174: 474-6.
7. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-9.
8. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16: 34-41.
9. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 656-8.
10. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased diseasefree survival in papillary thyroid cancer. Surgery 2001; 129(5): 552-8.
11. Sharma SV, Settleman J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-31.
12. Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, et al. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 2011; 12(5): 458-65.
13. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95(6): 2588-95.
14. Lanzi C, Cassinelli, G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009; 77: 297-309.
15. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16: 441-67.
16. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 2010; 20(9): 965-74.
17. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327-37.
18. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-96.
19. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101(9): 3597-605.
20. Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs 2004; 5: 1329-39.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3):205-16.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958; 53: 457-81.
23. Jung, F.H., Ple, P. Quinoline derivatives. US7973164 (2005).
24. Griffin, J.H., Briesewitz, R., Wray, J.W. Indolinone derivatives. US7223783 (2007).
25. Dumas, J., Scott, W.J., Elting, J., Hatoum-Makdad, H. Aryl ureas with angiogenesis inhibiting activity. US7838541 (2011).
26. Riedl, B., Dumas, J., Khire, U., Lowinger, T.B., Scott, W.J., Smith, R.A., Wood, J.E., Natero, R.W-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors. US8124630 (2012).
27. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-9.
28. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27(10): 1675-84.
29. Pasqualetti G, Ricci S, Dardano A, Ferdeghini M, Del Tacca M, Monzani F. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: Our experience and review of literature. Mini Rev Med Chem 2011; 11: 746-52.
30. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16(21):5260-8.
31. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, et al. Phase 2 study of sunitinib in refractory thyroid cancer. Annual Meeting of the American Society of Clinical Oncology, Chicago, USA (2008).
32. Ravaud A, de la Fouchardière C, Courbon C, Asselineau J, Klein M, Nicoli-Sire P, et al. Sunitinib in patients with refractory advanced thyroid cancer: The THYSU phase II trial. Annual Meeting of the American Society of Clinical Oncology, Chicago, USA (2008).
33. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011; 2011: 985780.
34. Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 2012; 83: 1041-48.
35. Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab 2012; Mar 22 [Epub ahead of print].
36. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7(5): 401-9.
37. Then, B.T., Huang, D., Furge, K., Kahnoski, R. IL-8 as a biomarker for sunitinib resistance. US8133686 (2009).
38. Yamamoto, Y., Watanabe, T., Okada, M., Tsuruoka, A. c-Kit kinase inhibitor. US7994159 (2011).